Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention? "window" Analysis from the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents)

JACC: Cardiovascular Interventions

Volumn 8, Issue 15, 2015, Pages 1978-1987

  Kirtane, Ajay J ^a,b   Parikh, Puja B ^a   Stuckey, Thomas D ^c   Xu, Ke ^b   Witzenbichler, Bernhard ^d   Weisz, Giora ^a,b,e   Rinaldi, Michael J ^f   Neumann, Franz Josef ^g   Metzger, D Christopher ^h   Henry, Timothy D ^i,j   Cox, David A ^k   Duffy, Peter L ^l   Brodie, Bruce R ^c   Mazzaferri, Ernest L ^m   Parvataneni, Rupa ^b   Maehara, Akiko ^a,b   Généreux, Philippe ^a,b,n   Mehran, Roxana ^b,o   Stone, Gregg W ^a,b  

^a Howard Hughes Medical Institute   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c MOSES H CONE MEMORIAL HOSPITAL   (United States)

^d Amper Kliniken AG   (Germany)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

^f LEVINE CANCER INSTITUTE   (United States)

^g UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^h Wellmont CVA Heart Institute   (United States)

ⁱ ABBOTT NORTHWESTERN HOSPITAL   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k LEHIGH VALLEY HOSPITAL   (United States)

^l Reid Heart Center   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^o MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

hemorrhage; platelets; stent(s); thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG ELUTING CARDIOVASCULAR STENT; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; STENT THROMBOSIS; THERAPEUTIC INDEX; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY DISEASE; CORONARY THROMBOSIS; DEVICES; DRUG EFFECTS; DRUG ELUTING STENT; DRUG RESISTANCE; GERMANY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSTHESIS DESIGN; REGISTER; RISK FACTOR; THROMBOCYTE; TIME FACTOR; UNITED STATES;

AGED; ASPIRIN; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; CORONARY THROMBOSIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; GERMANY; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84952042911     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.08.032     Document Type: Article

References (26)

1. P.A. Gurbel, K.P. Bliden, K. Guyer, and et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
2. N.J. Breet, J.W. van Werkum, H.J. Bouman, and et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
3. S.S. Brar, J. ten Berg, R. Marcucci, and et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
4. 12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
5. D. Sibbing, S. Braun, T. Morath, and et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
6. U.S. Tantry, L. Bonello, D. Aradi, et al. for the Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
7. G.W. Stone, B. Witzenbichler, G. Weisz, et al. for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
8. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834
9. P.A. Gurbel, K.P. Bliden, I.A. Navickas, and et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 160 2010 346 354
10. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schomig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 2010 317 318
11. F. Mangiacapra, G. Patti, E. Barbato, and et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study J Am Coll Cardiol Intv 5 2012 281 289
12. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
13. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, and et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
14. M.J. Price, P.B. Berger, P.S. Teirstein, et al. for the GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
15. D. Trenk, G.W. Stone, M. Gawaz, and et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
16. J.P. Collet, T. Cuisset, G. Range, et al. for the ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
17. S.D. Wiviott, E. Braunwald, C.H. McCabe, et al. for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
18. L. Wallentin, R.C. Becker, A. Budaj, et al. for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
19. S.R. Mehta, J.F. Tanguay, J.W. Eikelboom, et al. for the CURRENT-OASIS 7 Trial Investigators Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
20. T. Cuisset, G. Cayla, C. Frere, and et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome: Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
21. G. Patti, V. Pasceri, V. Vizzi, E. Ricottini, and G. Di Sciascio Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study) Am J Cardiol 107 2011 995 1000
22. R. Mehran, S.J. Pocock, E. Nikolsky, and et al. A risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol 55 2010 2556 2566
23. S.V. Manoukian, F. Feit, R. Mehran, and et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial J Am Coll Cardiol 49 2007 1362 1368
24. A.K. Chhatriwalla, A.P. Amin, K.F. Kennedy, et al. for the National Cardiovascular Data Registry Association between bleeding events and in-hospital mortality after percutaneous coronary intervention JAMA 309 2013 1022 1029
25. E. Mahla, T.A. Suarez, K.P. Bliden, and et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 5 2012 261 269
26. M. Kerneis, J. Silvain, J. Abtan, and et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel J Am Coll Cardiol Intv 6 2013 158 165